Lifeboat Foundation

Indeed, if we set ethical and safety objections aside, genetic enhancement has the potential to bring about significant national advantages. Even marginal increases in intelligence via gene editing could have significant effects on a nation’s economic growth. Certain genes could give some athletes an edge in intense international competitions. Other genes may have an effect on violent tendencies, suggesting genetic engineering could reduce crime rates.

We may soon be able to edit people’s DNA to cure diseases like cancer, but will this lead to designer babies? If so, bioethicist G Owen Schaefer argues that China will lead the way.

More progress with senolytics for treating age related diseases and further vindication for the SENS approach to aging.

The open access paper linked below provides another reason to be optimistic about the therapies to clear senescent cells from old tissues that are presently under development. Here, the researchers created genetically engineered mice in which they could selectively trigger senescent cell death in lung tissues. In older mice, the result was improved pulmonary function, and other improvements in the state of lung tissue — turning back the clock on some of the detrimental age-related changes that take place in the lungs.

Cells become senescent in response to damage or environmental toxicity, or at the end of their replicative lifespan, or to assist in wound healing. The vast majority either destroy themselves or are destroyed by the immune system, but a few manage to linger on. Those few grow in numbers over the years, and more so once the immune system begins to decline and falter in its duties. Ever more senescent cells accumulate in tissues with advancing age, and they secrete a mix of signals that can encourage other cells to become senescent, increase inflammation, and destructively remodel nearby tissue structures. In small numbers senescent cells can help to resist cancer or assist healing, but in large numbers they contribute meaningfully to all of the symptoms and conditions of old age. They are one of the root causes of aging.

Continue reading “Removing Senescent Cells from the Lungs of Old Mice Improves Pulmonary Function and Reduces Age-Related Loss of Tissue Elasticity” »

Imagine a future where there is no need to cut down a tree and and reshape that raw material into a chair or table. Instead, we could grow our furniture by custom-engineering moss or mushrooms. Perhaps glowing bacteria will light our cities, and we’ll be able to bring back extinct species, or wipe out Lyme disease—or maybe even terraform Mars. Synthetic biology could help us accomplish all that, and more.

That’s the message of the latest video in a new mini-documentary Web series called Explorations, focusing on potentially transformative areas of scientific research: genomics, artificial intelligence, neurobiology, transportation, space exploration, and synthetic biology. It’s a passion project of entrepreneur Bryan Johnson, founder of OS Fund and the payments processing company Braintree.

Continue reading “How Scientists Plan to Grow Cities Out of Living Organisms” »

MIT engineers have developed a microfluidic device that replicates the neuromuscular junction—the vital connection where nerve meets muscle. The device, about the size of a U.S. quarter, contains a single muscle strip and a small set of motor neurons. Researchers can influence and observe the interactions between the two, within a realistic, three-dimensional matrix.

The researchers genetically modified the neurons in the device to respond to light. By shining light directly on the neurons, they can precisely stimulate these cells, which in turn send signals to excite the muscle fiber. The researchers also measured the force the muscle exerts within the device as it twitches or contracts in response.

The team’s results, published online today in Science Advances, may help scientists understand and identify drugs to treat amyotrophic lateral sclerosis (ALS), more commonly known as Lou Gehrig’s disease, as well as other neuromuscular-related conditions.

Continue reading “New microfluidic chip replicates muscle-nerve connection” »

Engenheiros da University of California, Berkeley construíram os primeiros, sensores sem fio do tamanho de poeira que podem ser implantados no organismo, trazendo mais perto o dia em que um dispositivo Fitbit poderia monitorar os nervos internos, músculos ou órgãos em tempo real.

A universal cancer vaccine is on the horizon after scientists discovered how to rewire immune cells to fight any type of disease.

The potential new therapy involves injecting tiny particles of genetic code into the body which travel to the immune cells and teach them to recognise specific cancers.

Although scientists have shown previously that is it is possible to engineer immune cells outside the body so they can spot cancer it is the first time it has happened inside cells.

Continue reading “Universal cancer vaccine on horizon after genetic breakthrough” »

Nice.

When we think of synthetic biology, we often think of engineering a cell to give it some useful function. But SEED 2016 had quite a few speakers working outside of a biological cell. Some broke open cells to utilize just the cellular machinery to create “cell-free” systems. Others showed what could be done inside of the computer (in silico) to improve our understanding and prediction of synthetic gene networks. Here, we’re highlighting SEED speakers who showed how both of these approaches can advance synthetic biology.

Cell-free synthetic biology

Continue reading “SEED 2016: What can we do outside of a cell?” »

Tempus fugit. I’m just about old enough to remember a time in which 2020 was the distant future of science fiction novels, too far away to be thinking about in concrete terms, a foreign and fantastical land in which anything might happen. Several anythings did in fact happen, such as the internet, and the ongoing revolution in biotechnology that has transformed the laboratory world but leaks into clinics only all too slowly. Here we are, however, close enough to be making plans and figuring out what we expect to be doing when the third decade of the 21st century gets underway. The fantastical becomes the mundane. We don’t yet have regeneration of organs and limbs, or therapies to greatly extend life, but for these and many other staples of golden age science fiction, the scientific community has come close enough to be able to talk in detail about the roads to achieving these goals.

Of all the things that researchers might achieve with biotechnology in the near future, control over aging is by far the most important. Aging is the greatest cause of death and suffering in the world, and none of us are getting any younger. That may change, however. SENS, the Strategies for Engineered Negligible Senescence, is a synthesis of the scientific view of aging as an accumulation of specific forms of cell and tissue damage, pulling in a century of evidence from many diverse areas of medical science to support this conclusion. Aging happens because the normal operation of our cellular biochemistry produces damage, wear and tear at the level of molecules and molecular structures, and some of that damage accumulates to cause failure of tissues and organs, and ultimately death.

Philadelphia, PA, USA / Mexico City, Mexico — Bioquark, Inc., (www.bioquark.com) a life sciences company focused on the development of novel bioproducts for complex regeneration, disease reversion, and aging, and RegenerAge SAPI de CV, (www.regenerage.clinic/en/) a clinical company focused on translational therapeutic applications of a range of regenerative and rejuvenation healthcare interventions, have announced a collaboration to focus on novel combinatorial approaches in human disease and wellness. SGR-Especializada (http://www.sgr-especializada.com/), regulatory experts in the Latin American healthcare market, assisted in the relationship.

“We are very excited about this collaboration with RegenerAge SAPI de CV,” said Ira S. Pastor, CEO, Bioquark Inc. “The natural synergy of our cellular and biologic to applications of regenerative and rejuvenative medicine will make for novel and transformational opportunities in a range of degenerative disorders.”

As we close in on $7 trillion in total annual health care expenditures around the globe ($1 trillion spent on pharmaceutical products; $200 billion on new R&D), we are simultaneously witnessing a paradoxical rise in the prevalence of all chronic degenerative diseases responsible for human suffering and death.

Continue reading “Bioquark Inc. and RegenerAge SAPI de CV to Collaborate on Clinical Regenerative Healthcare” »